Sema4 Holdings Corp. (SMFR): Price and Financial Metrics


Sema4 Holdings Corp. (SMFR): $2.16

0.18 (+9.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SMFR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SMFR Stock Price Chart Interactive Chart >

Price chart for SMFR

SMFR Price/Volume Stats

Current price $2.16 52-week high $15.21
Prev. close $1.98 52-week low $1.49
Day low $1.94 Volume 1,618,600
Day high $2.17 Avg. volume 1,734,275
50-day MA $2.41 Dividend yield N/A
200-day MA $5.20 Market Cap 528.61M

Sema4 Holdings Corp. (SMFR) Company Bio


Sema4 Holdings Corp., doing business as Sema4, develops and operates health intelligence software solution that helps in diagnosis, treatment, and prevention of disease. The company offers solutions, such as Sema4, a solution that helps in treatment of the diseases; Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology; Sema4 Signal, a solution that provides data driven care solutions with analytics, digital tools, and exome based somatic and hereditary cancer genomic test; Biopharma, a solution that offers portfolio of health information, pre-clinical and clinical trial support, analytics for actionable insights, and advance sequencing services. It offers noninvasive prenatal select, a blood test for determining baby's health; expanded carrier screen, a carrier screen for more than 280 inherited conditions if one is pregnant or planning for pregnancy; and CarrierCheck, a genetic screen for 67 inherited conditions to know how DNA could affect the children. The company also provides Natalis newborn screen, a home-test to know baby's health by screening for 193 childhood diseases; Solid Tumor panel to analyze cancer driven genes; and test catalogue, a comprehensive offering of genetic and genomic tests. In addition, it owns and operates Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology. The company's solutions include women's health, oncology, expanded carrier screen, noninvasive prenatal select, Natali's newborn screen, hereditary cancer. Sema4 Holdings Corp. is based in Stamford, Connecticut.


SMFR Latest News Stream


Event/Time News Detail
Loading, please wait...

SMFR Latest Social Stream


Loading social stream, please wait...

View Full SMFR Social Stream

Latest SMFR News From Around the Web

Below are the latest news stories about Sema4 Holdings Corp that investors may wish to consider to help them evaluate SMFR as an investment opportunity.

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET

Yahoo | February 22, 2022

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

Innovators in the application of multi-omics to drug discovery – including phenomics and genomics – to initiate up to 10 therapeutic programs Sema4 Founder & CEO Eric Schadt and BioSymetrics Co-Founder and CEO Anthony Iacovone discuss the collaboration between the two companies STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a phenomics-driven drug discovery com

Yahoo | February 22, 2022

Sema4 to Participate at Two Upcoming Investor Conferences in February

STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceFireside chat and 1x1s on Thursday, February 17th, 2022 at 10:00 a.m. ET SVB Leerink 11th Annual Global Healthcare ConferenceFormal presentation and 1x1s on Friday, February 18th, 2

Yahoo | February 3, 2022

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities

30-year industry veteran, Jerry Conway, joins Sema4 as Senior Vice President of Market Access to lead the team Jerry Conway Jerry Conway joins Sema4 as Senior Vice President of Market Access STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access team to drive increased market access for the company’s platform. The team’s key initiatives include improving c

Yahoo | February 1, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o

Yahoo | January 18, 2022

Read More 'SMFR' Stories Here

SMFR Price Returns

1-mo -4.42%
3-mo -37.21%
6-mo -67.22%
1-year -82.94%
3-year N/A
5-year N/A
YTD -51.57%
2021 -59.60%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7198 seconds.